摘要鞘内药物输注系统(IDDS)永久植入术治疗顽固性疼痛病人18例,其中晚期癌痛病人13例,非癌痛病人5例.首先行筛选试验,随后行IDDS永久植入术.癌痛病人采用视觉模拟评分(VAS评分)及QLQ-C30生活质量评分(QLQ-C30)法,非癌痛病人采用VAS评分法,评价疼痛程度,记录副作用及并发症的发生情况,癌痛病人随访至死亡,非癌痛病人均获得随访至今.术后所有病人经短期鞘内给药量调整后,VAS评分降低,癌痛病人QLQ-C30评分升高.部分病人出现恶心呕吐、便秘、尿潴留、皮肤瘙痒、镇静过度等,约1周均明显缓解,无持续残留症状.术中拔除穿刺针时误割断鞘内导管1例;导管与泵的金属接口过度磨擦至导管破裂,出现渗液1例;术后出现低颅压2例,脑脊液渗漏1例,右小腿后外侧持续性神经病理性疼痛1例,无伤口感染、裂开、愈合不良,无导管渗漏、破裂、异位、折叠、被结扎或肉芽肿形成,无泵翻转、位置异常等,设备本身无故障出现.

abstractsFrom November 2003 to May 2010, intrathecal drug delivery system (IDDS) was implanted in 18 patients with chronic intractable pain. Analgesia was provided with morphine. Thirteen patients suffered from late stage cancer and 5 from diseases other than cancer. VAS score was used to measure intensity of pain in all 18patients. QLQ-C30 score was used to evaluate quality of life in cancer patients. The patients were followed up for 3-62 months in 5 non-cancer patients. All 13 cancer patients died at 57 days-10 months after operation. VAS scores were significantly decreased and QLQ-C30 scores increased by intrathecal administration of morphine. Side effects developed in all patients to some extent including nausea, vomiting, constipation, urinary retention, pruritus and over-sedation and vanished in a week. Intrathecal catheter was cut while being pulled out of the needle in 1 patient. Two patients developed low intracranial pressure after operation. Cerebrospinal fluid leakage occurred in 1 patient. One patient developed neuropathic pain in the posterolateral side of right leg.